Create Free Account

By creating account you will get access to hot stocks & personalised emails

Impedimed Ltd

Healthcare AU IPD

0.093AUD
0.003(3.33%)

Last update at 2024-04-24T00:56:00Z

Day Range

0.090.09
LowHigh

52 Week Range

0.080.24
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax -20.49000M -19.82800M -20.66700M -21.32900M -23.94500M
Minority interest - - - - -
Net income -20.52100M -19.87400M -20.70600M -21.37700M -23.99600M
Selling general administrative 19.51M 18.15M 21.42M 18.81M 19.97M
Selling and marketing expenses 0.46M 0.67M 0.45M 0.88M 0.71M
Gross profit 9.70M 8.79M 6.75M 4.02M 2.85M
Reconciled depreciation 2.50M 2.77M 1.70M 1.44M 0.68M
Ebit -22.99300M -21.53700M -23.07300M -25.55700M -27.01200M
Ebitda -20.49300M -18.76800M -21.37300M -24.12100M -26.33000M
Depreciation and amortization 2.50M 2.77M 1.70M 1.44M 0.68M
Non operating income net other - - - - -
Operating income -22.86500M -21.46600M -22.96700M -25.51000M -27.01200M
Other operating expenses 32.60M 30.41M 29.05M 27.11M 31.11M
Interest expense 0.77M 0.02M 2.41M 4.23M 2.94M
Tax provision 0.03M 0.05M 0.04M 0.05M 0.05M
Interest income 0.80M 0.05M 0.02M 0.04M 0.37M
Net interest income 0.77M 0.02M -0.05200M 0.04M 0.37M
Extraordinary items - - - 0.00000M -0.12700M
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.03M 0.05M 0.04M 0.05M 0.05M
Total revenue 11.25M 10.49M 8.35M 5.69M 4.10M
Total operating expenses 32.70M 30.32M 29.82M 29.57M 29.86M
Cost of revenue 1.55M 1.71M 1.60M 1.68M 1.25M
Total other income expense net 1.70M 1.69M 2.44M 4.19M 3.07M
Discontinued operations - - - - -0.12700M
Net income from continuing ops -20.52100M -19.87400M -20.70600M -21.37700M -23.99600M
Net income applicable to common shares -20.52100M -19.87400M -20.70600M -21.37700M -24.12300M
Preferred stock and other adjustments - - - - -
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Total assets 68.74M 58.70M 34.20M 33.06M 22.58M
Intangible assets 12.04M 8.74M 5.04M 3.89M 2.79M
Earning assets - - - - -
Other current assets 0.54M 0.97M 0.90M 0.79M 0.50M
Total liab 7.86M 7.66M 8.69M 5.70M 6.80M
Total stockholder equity 60.88M 51.04M 25.51M 27.36M 15.79M
Deferred long term liab - - - - -
Other current liab 1.03M 0.93M 0.88M 0.58M 4.58M
Common stock 336.09M 307.56M 267.27M 250.56M 219.73M
Capital stock 336.09M 307.56M 267.27M 250.56M 219.73M
Retained earnings -311.16200M -290.64100M -270.76700M -250.06100M -228.71700M
Other liab 0.86M 0.41M 0.40M 0.09M 0.14M
Good will 2.73M 2.63M 2.42M 2.64M 2.58M
Other assets - 0.26M - - -
Cash 45.71M 40.73M 19.68M 19.66M 11.33M
Cash and equivalents 13.55M 31.29M 11.50M 8.78M 8.16M
Total current liabilities 5.85M 7.24M 8.13M 5.11M 6.66M
Current deferred revenue 3.16M 3.51M 5.65M 2.25M -0.36400M
Net debt -44.26300M -40.56000M -19.20700M -18.79200M -10.45900M
Short term debt 0.30M 0.17M 0.32M 0.36M 0.36M
Short long term debt - - - - -
Short long term debt total 1.45M 0.17M 0.47M 0.87M 0.87M
Other stockholder equity 8.05M 34.13M 29.01M 26.86M 24.77M
Property plant equipment 1.95M 0.42M 1.03M 1.01M 0.19M
Total current assets 51.94M 46.66M 25.65M 25.45M 16.97M
Long term investments 0.08M 0.07M 0.07M 0.08M 0.04M
Net tangible assets 46.11M 39.68M 18.06M 20.84M 10.41M
Short term investments - - - - -
Net receivables 3.84M 3.41M 3.71M 3.73M 3.49M
Long term debt - - - - -
Inventory 0.81M 0.93M 0.37M 0.86M 1.12M
Accounts payable 1.35M 2.64M 1.30M 1.91M 2.09M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 35.95M 34.13M 29.01M 26.86M 24.77M
Additional paid in capital - - - - -
Common stock total equity - - - 250.56M 219.73M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other -16.80100M 0.18M -8.55500M -7.61400M 5.61M
Deferred long term asset charges - - - - -
Non current assets total 16.80M 12.04M 8.55M 7.61M 5.61M
Capital lease obligations 1.45M 0.17M 0.47M 0.87M -
Long term debt total 1.15M 0.00000M 0.16M 0.51M 0.00000M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments -6.04300M -5.22100M -2.45700M -2.16100M -1.76500M
Change to liabilities -0.89400M 1.53M -0.28300M -0.05800M 0.45M
Total cashflows from investing activities -6.04300M -5.22100M -2.45700M -2.16100M -1.76500M
Net borrowings -0.42500M -0.37300M -0.24000M -0.41300M -0.41300M
Total cash from financing activities 27.93M 39.92M 16.47M 30.16M 0.14M
Change to operating activities 0.17M -2.79400M 2.65M -1.82600M -0.16800M
Net income -20.52100M -19.87400M -20.70600M -21.37700M -23.99600M
Change in cash 4.98M 21.05M 0.02M 8.33M -20.01500M
Begin period cash flow 40.73M 19.68M 19.66M 11.33M 31.34M
End period cash flow 45.71M 40.73M 19.68M 19.66M 11.33M
Total cash from operating activities -18.04900M -15.66400M -13.25800M -19.21800M -19.58800M
Issuance of capital stock 30.02M 42.50M 16.84M 33.25M 0.16M
Depreciation 0.68M 1.24M 0.35M 0.46M 0.68M
Other cashflows from investing activities - - - 0.00000M 0.46M
Dividends paid -0.42500M -0.37300M -0.58000M -0.41300M -
Change to inventory 0.12M -0.55400M 0.49M 0.26M 0.69M
Change to account receivables 0.18M 0.04M -0.08400M -0.25600M 0.61M
Sale purchase of stock -1.51600M -2.21300M -0.13300M -2.67900M -0.01800M
Other cashflows from financing activities 0.28M 0.37M 0.75M 0.41M -1.76500M
Change to netincome 0.30M 2.95M 2.97M 2.61M 2.27M
Capital expenditures 6.04M 5.22M 2.46M 2.16M 2.22M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.29M -0.51500M 0.41M 0.00100M -15.53500M
Stock based compensation 0.75M 3.00M 3.04M 2.25M -
Other non cash items 1.79M 2.97M 7.09M 1.70M 23.44M
Free cash flow -24.09200M -20.88500M -15.71500M -21.37900M -21.81200M

Fundamentals

  • Previous Close 0.09
  • Market Cap182.08M
  • Volume410498
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-22.88200M
  • Revenue TTM10.47M
  • Revenue Per Share TTM0.005
  • Gross Profit TTM 9.80M
  • Diluted EPS TTM-0.01

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
IPD
Impedimed Ltd		 0.003 3.33% 0.09 - - 17.77 3.65 14.55 -7.091
COH
Cochlear Ltd		 2.37 0.73% 325.42 60.26 46.30 9.75 11.76 9.62 36.63
PNV
Polynovo Ltd		 0.14 7.34% 2.12 - 140.85 17.37 21.49 17.51 647.42
AVR
Anteris Technologies Ltd		 -0.18 0.78% 22.92 - - 104.23 14.98 95.15 -5.9152
AVH
Avita Therapeutics Inc		 0.04 1.44% 2.82 - - 8.59 5.71 6.72 -10.0538

Reports Covered

Stock Research & News

View All

Profile

ImpediMed Limited, a medical technology company, develops, manufactures, and sells bioimpedance spectroscopy (BIS) devices and software services in Australia, North America, and internationally. The company offers SOZO, a noninvasive BIS device for the assessment of lymphedema, and deliver snapshot of fluid status and tissue composition; SFB7, a single-channel, tetrapolar BIS device to analyze body composition in healthy individuals; and ImpediVET, a single-channel, tetrapolar (BIS) device that measures fluid status and tissue composition for veterinary applications. It sells its devices to hospitals and clinics. The company was incorporated in 1999 and is headquartered in Pinkenba, Australia.

Impedimed Ltd

50 Parker Court, Pinkenba, QLD, Australia, 4008

Key Executives

Name Title Year Born
Mr. Timothy Cruickshank Chief Financial Officer NA
Mr. Shashi Tripathi COO, CTO & Chief Customer Officer NA
Mr. Dennis Schlaht Sr. VP of R&D and Technology NA
Ms. Catherine Kingsford Sr. VP of Medical Affairs NA
Mr. David W. Anderson B.S. Exec. Director 1954
Mr. Richard P. Valencia MD & CEO 1962
Mr. Michael John Bassett Chief Commercial Officer, Sr. VP of Corp. & Strategic Devel. and GM of Renal NA
Ms. Nancy T. Deisinger Sr. VP of HR NA
Dr. Thomas Schenk Chief Medical Officer NA
Ms. Leanne Ralph AAICD, ACIS, BBus Company Sec. NA

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).

Our Company

Useful Links

Contact Us

Market Research

Our Company

Useful Links

Contact Us

Disclaimer

The information given by Kalkine Pty Ltd ABN34 154 808 312 (Australian Financial Services License Number 425376) on this website is general information or advice only.

It does not take into account any of your personal objectives, circumstances or needs. Choosing an investment is an important decision. If you do not feel confident making a decision based on the recommendations Kalkine has made in our reports, you should consider obtaining personal advice from an authorised adviser.

There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. Terms & Conditions have been provided for our services, please go through them and also read our Financial Services Guide.

Our website may contain information on past performance of particular investments. Past performance is not an indicator of future performance. Hypothetical returns may not reflect actual performance. Any displays of potential investment opportunities are for sample purposes only and may not actually be available to investors.

The information on the website does not constitute an offer to sell securities or a solicitation of an offer to buy securities. Our reports contain general recommendations to invest in securities.

Copyright 2024 Krish Capital Pty. Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.